Search
ATAI Life Sciences NV
ATAIAdd to Watchlist
4.880USD
-0.390-7.40%
Close 07/01, 16:00（ET）Quotes delayed by 15 min
1.80BMarket Cap
LossP/E TTM
Earnings Forecast
Currency: USD Updated: 2026-07-01The current earnings forecast score of ATAI Life Sciences NV is 8.43, ranking 125 out of 387 in the Biotechnology & Medical Research industry. The average price target is 12.00, with a high of 16.00 and a low of 7.00.
Analyst Rating
Based on
15
analysts
Buy
Current Rating
13.833
Target Price
+162.49%
Upside Space
Strong Buy
Buy
Hold
Sell
Strong Sell
Peer Comparison
562
Total
5
Median
6
Average
Company name
Ratings
Analysts
ATAI Life Sciences NV
ATAI
15
Beigene Ltd
ONC
27
CRISPR Therapeutics AG
CRSP
27
Ionis Pharmaceuticals Inc
IONS
27
argenx SE
ARGX
26
IQVIA Holdings Inc
IQV
26
1
2
3
...
113
Support & Resistance
Relevant data have not been disclosed by the company yet.
Financial Forecasting
EPS
Revenue
Net Profit
EBIT
Forecast
Actual
FAQs
What is ATAI Life Sciences NV's expected revenue for the next quarter?
ATAI Life Sciences NV's expected revenue is 11.11K.
What is ATAI Life Sciences NV's price target?
Analysts forecast that ATAI Life Sciences NV's price target is USD 12.00, with the highest forecast at USD 16.00 and the lowest forecast at USD 7.00.
How have ATAI Life Sciences NVATAI's recent earnings per share performed?
The market expectation was USD -0.08, while ATAI Life Sciences NVATAI's earnings per share (EPS) for the previous quarter was USD -1.73. EPS for the next quarter is expected at USD -0.10.
What is the analyst rating for ATAI Life Sciences NV?
Based on the ratings of ATAI Life Sciences NV's stock from 15 analysts, most analysts support a Buy trend. After considering the opinions of other analysts, we ultimately rate Apple's stock as Buy. Please note that this is not trading advice. You still need to conduct your own analysis.